CLINICAL_TRIALS ClinicalTrials.gov record update

Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01015833
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:33.193992+00:00
Published At: 2018-05-02T00:00:00+00:00
Record Updated At: 2022-08-04
Results Posted At: 2018-05-02
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Advanced Adult Hepatocellular Carcinoma", "Recurrent Hepatocellular Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v7", "Stage IIIA Hepatocellular Carcinoma AJCC v7", "Stage IIIB Hepatocellular Carcinoma AJCC v7", "Stage IIIC Hepatocellular Carcinoma AJCC v7", "Stage IV Hepatocellular Carcinoma AJCC v7", "Stage IVA Hepatocellular Carcinoma AJCC v7", "Stage IVB Hepatocellular Carcinoma AJCC v7", "Unresectable Hepatocellular Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-08-04"
protocolSection.identificationModule.nctId: "NCT01015833"
protocolSection.identificationModule.officialTitle: "Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2018-05-02"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.